ReviewBiomedicines2022
Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review and Meta-analysis of Survival Prediction in Glioblastoma Patients using Advanced MRI Techniques.Current medical imaging · 2026Pooled it
- Obstacles and Trials in Treating Primary Brain Tumors.International journal of molecular sciences · 2026Review
- Amsterdam IMAging and Clinical GliOma Dataset; IMAGO.Scientific data · 2026Article
- Post-Treatment MRI Features on First Follow-Up Imaging in Diffuse Gliomas After Near-Total Resection: A Real-World Exploratory Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- mRNA-based MRI contrast agent for precise diagnosis of glioma and pseudoprogression.Cell biomaterials · 2026Article
- Article
- Ataxin-2 as a candidate blood biomarker for estimating disease status in cases of suspected glioblastoma recurrence.Brain tumor pathology · 2026Article
- Amide proton transfer-weighted (APTw) CEST MRI in clinical routine for single time point diagnosis of pseudoprogression in IDH-wildtype glioblastoma.Neuro-oncology · 2026Article
- Radiomics and clinical data predict pseudoprogression after radiotherapy in high-grade glioma.Frontiers in oncology · 2026Article
- Beyond morphology: imaging the glioblastoma microenvironment in the era of quantitative neuro-oncology.Frontiers in medicine · 2026Review
- The Clinical Utility of Cell-Free DNA in Brain Tumor Management: A Comprehensive Review.Journal of molecular neuroscience : MN · 2025Review
- Artificial Intelligence in the Diagnosis and Treatment of Brain Gliomas.Biomedicines · 2025Review
- A self-supervised multimodal deep learning approach to differentiate post-radiotherapy progression from pseudoprogression in glioblastoma.Scientific reports · 2025Article
- An effective MRI perfusion threshold based workflow to triage additionalScientific reports · 2025Article
- Resolving spatial response heterogeneity in glioblastoma.European journal of nuclear medicine and molecular imaging · 2024Article
- Review
- Notch appearance as a novel radiological predictor of transient expansion and good outcome of expanding schwannoma after radiotherapy.Discover oncology · 2024Article
- The peritumoral brain zone in glioblastoma: a review of the pretreatment approach.Polish journal of radiology · 2024Review
- Artificial Intelligence in Neuroradiology: A Review of Current Topics and Competition Challenges.Diagnostics (Basel, Switzerland) · 2023Review
- Advanced Magnetic Resonance Imaging in the Evaluation of Treated Glioblastoma: A Pictorial Essay.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGlioblastoma is the most frequent malignant primitive brain tumor in adults. The treatment includes surgery, radiotherapy, and chemotherapy. During follow-up, combined chemoradiotherapy can induce treatment-related changes mimicking tumor progression on medical imaging, such as pseudoprogression (PsP). Differentiating PsP from true progression (TP) remains a challenge for radiologists and oncologists, who need to promptly start a second-line treatment in the case of TP. Advanced magnetic resonance imaging (MRI) techniques such as diffusion-weighted imaging, perfusion MRI, and proton magnetic resonance spectroscopic imaging are more efficient than conventional MRI in differentiating PsP from TP. None of these techniques are fully effective, but current advances in computer science and the advent of artificial intelligence are opening up new possibilities in the imaging field with radiomics (i.e., extraction of a large number of quantitative MRI features describing tumor density, texture, and geometry). These features are used to build predictive models for diagnosis, prognosis, and therapeutic response.
methodOut of 7350 records for MR spectroscopy, GBM, glioma, recurrence, diffusion, perfusion, pseudoprogression, radiomics, and advanced imaging, we screened 574 papers. A total of 228 were eligible, and we analyzed 72 of them, in order to establish the role of each imaging modality and the usefulness and limitations of radiomics analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.